Skip to main content

Gynecologic Cancers

Chicago, IL—The addition of the PD-1 inhibitor pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) resulted in a substantial and clinically meaningful improvement in overall survival (OS) in patients with persistent, recurrent, or metastatic cervical cancer, according to the final OS analysis of the phase 3 KEYNOTE-826 trial. The results were presented during the 2023 American Society of Clinical Oncology Annual Meeting. Read More ›

The following clinical trials represent a selection of key studies currently recruiting patients with gynecologic cancers for inclusion in investigations of new therapies and new regimens of existing treatments for the disease. Each clinical trial description includes the NLM Identifier to be used as a reference with This information can help oncology practice managers and providers direct eligible patients to one of these trials. Read More ›

Health insurance coverage mediated racial and ethnic inequities among patients with advanced-stage cervical cancer, according to findings from a recent retrospective, cross-sectional, population-based study. Read More ›

Vaccination against human papillomavirus (HPV) can prevent several types of cancer, including cervical, oral/oropharyngeal, penile, and anal cancers. Unfortunately, vaccination rates, as well as public knowledge regarding the link between HPV and these cancers, are lagging, according to research presented during the 2023 American Association for Cancer Research Annual Meeting. Read More ›

On February 9, 2023, the FDA approved dostarlimab-gxly (Jemperli; GlaxoSmithKline) for the treatment of adult patients with mismatch repair-deficient, recurrent or advanced endometrial cancer, as determined by an FDA-approved test, whose disease has progressed on or following a previous platinum-containing regimen in any setting and who are not candidates for curative surgery or radiation. Read More ›

Approximately 25% of women with gynecologic malignancies cannot afford the cost of their medical care, according to a study presented at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›

Participation in clinical trials may help to overcome health disparities in the treatment of advanced or recurrent ovarian cancer, and minority patients should be encouraged to participate, said Khilen B. Patel, MD, Obstetrics & Gynecology Resident, Medical College of Georgia, Augusta University, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer. Read More ›